Physician profile
Nathan C King
NPI 1861835035
$4,846.76
in general payments reported to CMS, 2019-2025
30 companies · $529 in 2025
The $529 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $842 · 2020: $614 · 2021: $935 · 2022: $444 · 2023: $827 · 2024: $655 · 2025: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,010.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,114.95 | 2019-2025 | |
| Amgen INC. | $647.17 | 2019-2025 | Evenity, Otezla, Repatha |
| Novo Nordisk INC | $612.58 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $536.23 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $369.74 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $228.37 | 2019-2024 | Breztri |
| Allergan, INC. | $176.66 | 2019-2020 | |
| Radius Health, INC. | $148.69 | 2019-2020 | |
| Catalyst Pharmaceuticals, INC. | $106.60 | 2023-2024 | Firdapse |
| Amarin Pharma, INC. | $96.88 | 2020-2023 | |
| Teva Pharmaceuticals USA, INC. | $93.37 | 2019-2023 | Ajovy |
| Glaxosmithkline, LLC. | $91.31 | 2019-2023 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $90.48 | 2021-2022 | |
| Boston Scientific Corporation | $72.96 | 2019 | |
| Philips North America LLC | $49.67 | 2024 | (Ck7) Extended Holter |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $46.35 | 2021-2025 | Nexletol |
| Gilead Sciences, INC. | $43.79 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $40.04 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.54 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $33.36 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $27.98 | 2021 | |
| Exact Sciences Corporation | $27.75 | 2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $23.46 | 2022 | |
| Leo Pharma INC. | $21.83 | 2021 | |
| Daiichi Sankyo INC. | $20.59 | 2020 | |
| Dermira, INC. | $19.86 | 2019 | |
| Eisai INC. | $18.46 | 2021 | |
| Nestle Healthcare Nutrition INC. | $18.21 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $16.90 | 2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $13.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.